Pneumology - Reviews Open access

Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials

Authors

Published
4 February 2022
Section
Pneumology - Reviews

Abstract

The effective treatment modalities for severe coronavirus disease 2019 (COVID-19) are needed. As the primary cause of mortality is a hyperinflammatory state, the interleukin-6 antagonist tocilizumab has been used in multiple clinical studies. We conducted this systematic review and meta-analysis to estimate the effectiveness of tocilizumab in reduction of mortality due to COVID-19. A systematic search of the Pubmed and Embase databases was performed to extract randomized controlled trials (RCTs) regarding the use of tocilizumab therapy for COVID-19. An overall pooled mortality analysis was performed, and odds ratios were reported. Cochrane risk of bias assessment tool was used to assess the risk of bias. Heterogeneity was assessed using the I2 statistic. Nine RCTs, including 6489 patients, were selected for meta-analysis. Seven trials reported 28-day mortality, and one trial each reported 21-day and 30-day mortality. There were 846 deaths among 3358 participants in the steroid group while 943 deaths among 3131 patients randomized to the control group (random-effects odds ratio 0.87, 95% confidence interval 0.73-1.03, p=0.11). There was some heterogeneity among the trials as the I2 value was 15%, with a p-value of 0.31. There was a reduction in the need for ICU admission in the tocilizumab group. A higher risk of secondary infections was noted in the tocilizumab group (fixed-effects odds ratio 0.72, 95% confidence interval 0.55-0.95, p=0.02). This meta-analysis of RCTs demonstrated that the use of tocilizumab was not associated with a reduction in all-cause mortality in patients with COVID-19 and had higher odds of secondary infections.  

References

  1. Aggarwal N, Boppana TK, Mittal S. COVID-19 pandemic: The testing times for healthcare workers. Monaldi Arch Chest Dis 2021;91:1515. DOI: https://doi.org/10.4081/monaldi.2021.1515
  2. Sehgal IS, Guleria R, Singh S, et al. A randomised trial of Mycobacterium w in critically ill patients with COVID-19: ARMY-1. ERJ Open Research 2021;7:00059-2021. DOI: https://doi.org/10.1183/23120541.00059-2021
  3. Boppana TK, Mohan A, Madan K, et al. Candidate immunomodulators for COVID-19: Heat-killed Mycobacterium w and BCG vaccine. Adv Respir Med 2021;89:350–1. DOI: https://doi.org/10.5603/ARM.a2021.0043
  4. Sryma PB, Mittal S, Madan K, et al. Reinventing the wheel in ARDS: Awake proning in COVID-19. Arch Bronconeumol 2020;56:747–9. DOI: https://doi.org/10.1016/j.arbres.2020.06.002
  5. Sryma P, Mittal S, Madan K, et al. Awake prone positioning in non-intubated patients for the management of hypoxemia in COVID-19: A systematic review and meta-analysis. Monaldi Arch Chest Dis 2021;91:1623. DOI: https://doi.org/10.4081/monaldi.2021.1623
  6. Li P, Lu Z, Li Q, et al. Administration timing and efficacy of tocilizumab in patients With COVID-19 and elevated IL-6. Front Mol Biosci 2021;8:651662. DOI: https://doi.org/10.3389/fmolb.2021.651662
  7. Gritti G, Raimondi F, Bottazzi B, et al. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. Leukemia 2021;2710-4 DOI: https://doi.org/10.1038/s41375-021-01299-x
  8. Corominas H, Castellví I, Diaz-Torné C, et al. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2. Medicine (Baltimore) 2021;100:e25923. DOI: https://doi.org/10.1097/MD.0000000000025923
  9. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397:1637–45. DOI: https://doi.org/10.1016/S0140-6736(21)00676-0
  10. Hermine O, Mariette X, Tharaux P-L, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Intern Med 2021;181:32–40.
  11. Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021;384:20–30. DOI: https://doi.org/10.1056/NEJMoa2030340
  12. Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern Med 2021;181:24–31. DOI: https://doi.org/10.1001/jamainternmed.2020.6615
  13. Elavarasi A, Sahoo RK, Seth T, et al. Anti-interleukin-6 therapies for Covid-19: A systematic review, critical appraisal and meta-analysis. Natl Med J India 2020;33:152–7. DOI: https://doi.org/10.4103/0970-258X.288119
  14. Cortegiani A, Ippolito M, Einav S. Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Pulmonology 2021;27:52-66. DOI: https://doi.org/10.1016/j.pulmoe.2020.07.003
  15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700–b2700. DOI: https://doi.org/10.1136/bmj.b2700
  16. Mariette X, Hermine O, Tharaux P-L, et al. Effectiveness of tocilizumab in patients hospitalized with COVID-19: A follow-up of the CORIMUNO-TOCI-1 randomized clinical trial. JAMA Intern Med 2021;181:1241–3. DOI: https://doi.org/10.1001/jamainternmed.2021.2209
  17. Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Biomed Pharmacother 2021;133:110825. DOI: https://doi.org/10.1016/j.biopha.2020.110825
  18. Gordon AC, Mouncey PR, Al-Beidh F et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 2021;384:1491–502. DOI: https://doi.org/10.1056/NEJMoa2100433
  19. Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med 2021;9:511–21. DOI: https://doi.org/10.1016/S2213-2600(21)00081-3
  20. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med 2021;384:1503–16. DOI: https://doi.org/10.1056/NEJMoa2028700
  21. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020;383:2333–44. DOI: https://doi.org/10.1056/NEJMoa2028836
  22. Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ 2021;372:n84. DOI: https://doi.org/10.1136/bmj.n84
  23. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA 2020;324:1330-41. DOI: https://doi.org/10.1001/jama.2020.17023
  24. Mittal S, Madan K, Mohan A, et al. Diabetes in COVID-19: Steroid effect. J Med Virol 2021;93:4166. DOI: https://doi.org/10.1002/jmv.26457
  25. Oliynyk O, Barg W, Slifirczyk A, et al. Efficacy of tocilizumab therapy in different subtypes of COVID-19 cytokine storm syndrome. Viruses 2021;13:1067. DOI: https://doi.org/10.3390/v13061067
  26. Rosas IO, Diaz G, Gottlieb RL, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med 2021;47:1258-70. DOI: https://doi.org/10.1007/s00134-021-06507-x
  27. Hamed DM, Belhoul KM, Al Maazmi NA, et al. Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison. J Infect Public Health 2021;14:985-9. DOI: https://doi.org/10.1016/j.jiph.2021.06.003
  28. Declercq J, Van Damme KFA, De Leeuw E, et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respir Med 2021;9:1427-38. DOI: https://doi.org/10.1016/S2213-2600(21)00377-5

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.